Yahoo · Sep 4, 2026
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
IO
NASDAQ · IONS
Ionis Pharmaceuticals, Inc.
Healthcare · Biotechnology
$56.02
Down-$0.37 (-0.66%)
Updated Sep 11, 2026, 12:18 AM
SID Score
4.5/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 12.57B
- P/E ratio
- -49.61
- Dividend yield
- 0.00%
- 52-week range
- $50.01 – $86.74
- Volume
- 3.04M
- Avg. volume
- 2.43M
Price performance
IONS price history
1M range · 19 trading sessions · Daily adjusted prices
IONS closed at $56.02 after 19 trading sessions, up 0.27% for the selected period.
- Last close
- $56.02
- Period change
- +0.27%
- Period low
- $55.87
- Period high
- $63.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $56.38 | $56.9569 | $55.695 | $56.02 | 3.04M |
| Sep 8, 2026 | $52.15 | $57.4292 | $52.15 | $56.71 | 9.18M |
| Sep 4, 2026 | $58.36 | $58.96 | $57.78 | $58.09 | 2.67M |
| Sep 3, 2026 | $60.42 | $60.42 | $57.47 | $58.13 | 4.35M |
| Sep 2, 2026 | $60.25 | $61.77 | $59.775 | $61.33 | 1.85M |
| Sep 1, 2026 | $60.37 | $60.99 | $59.78 | $59.88 | 1.87M |
| Aug 31, 2026 | $61.065 | $61.065 | $59.70 | $60.36 | 2.02M |
| Aug 28, 2026 | $60.62 | $61.69 | $60.35 | $61.05 | 1.85M |
| Aug 27, 2026 | $63.48 | $63.48 | $62.34 | $62.43 | 1.63M |
| Aug 26, 2026 | $63.50 | $63.55 | $62.44 | $63.36 | 2.15M |
| Aug 25, 2026 | $62.53 | $64.19 | $62.19 | $63.57 | 2.44M |
| Aug 24, 2026 | $60.535 | $62.07 | $59.70 | $62.04 | 2.21M |
| Aug 21, 2026 | $59.64 | $60.915 | $59.0601 | $59.74 | 2.72M |
| Aug 20, 2026 | $60.025 | $60.41 | $58.60 | $58.76 | 2.12M |
| Aug 19, 2026 | $60.11 | $61.355 | $59.61 | $60.80 | 3.14M |
| Aug 18, 2026 | $58.405 | $60.19 | $58.0237 | $59.62 | 3.19M |
| Aug 17, 2026 | $57.11 | $58.74 | $56.41 | $58.63 | 2M |
| Aug 14, 2026 | $55.16 | $57.24 | $55.16 | $57.24 | 1.35M |
| Aug 13, 2026 | $56.50 | $56.81 | $55.56 | $55.87 | 1.22M |
Latest IONS news
The latest Smart Investors Daily articles mentioning IONS.
Stock researchCompany · Overview
IONS research
Overview
Company profile and research snapshot.
Company profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $83.85
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Barclays | Overweight | — |
| Sep 8, 2026 | Morgan Stanley | Overweight | — |
| Sep 8, 2026 | Goldman Sachs | Neutral | — |
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Sep 8, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene. The approval includes a bro
SeekingAlpha · Sep 4, 2026
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease September 4, 2026 10:00 AM EDTCompany...
Yahoo · Sep 4, 2026
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc. (NASDAQ:IONS), for Alexander disease in adult and pediatric patients. Zanvastro becomes the first and only disease-modifying therapy available for this ultra-rare, progressive, and frequently fatal neurological disorder. Prior to this regulatory authorization, clinical care for affected individuals remained strictly limited to symptom management. First Approved Disease-Modifying
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
